Clinical Trials

Hypopharyngeal Neoplasms

NCT03708822 2024-01-18

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

48 enrolled

Nasopharyngeal Carcinoma

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05262335 2023-11-28

ALTER-G-001

116 enrolled

Digestive System Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Gynecologic

Uterine Cervical Neoplasms

NCT06107114 2023-11-22

CZCNRHNSCC

52 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02624128 2023-11-13

V-CHANCE

39 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT04920344 2023-11-03

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

15 enrolled

Oropharyngeal Neoplasms

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

136 enrolled

Triple Negative Breast Neoplasms

NCT06023875 2023-09-05

NCCCNRHNSCC

Squamous Cell Carcinoma of Head and Neck

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

51 enrolled

Hypopharyngeal Neoplasms

NCT04297995 2023-08-08

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

131 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02760667 2023-06-27

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

20 enrolled

Head and Neck Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT02560298 2023-06-22

InterAACT

91 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT05877911 2023-05-26

Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy

110 enrolled

GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Acute Kidney Injury

NCT04542369 2023-05-03

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

15 enrolled

Small Cell Lung Carcinoma

NCT05828381 2023-04-25

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

33 enrolled

Esophageal Neoplasms

NCT04389177 2023-04-10

Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT00492778 2023-03-29

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

165 enrolled 15 charts

Gynecologic

Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation

NCT05772377 2023-03-16

Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer

36 enrolled

Gynecologic

To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer

NCT02099175 2023-03-13

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

41 enrolled

Sinonasal Tumors

NCT02099188 2023-03-13

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

27 enrolled

Unresectable Sinonasal Tumors

NCT05749042 2023-03-01

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

70 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

70 enrolled

Cholangiocarcinoma

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

40 enrolled

Resectable Biliary Tract Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05637268 2022-12-05

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

23 enrolled

Esophageal Neoplasms

NCT05596890 2022-11-28

PICCRT

50 enrolled

Esophageal Squamous Cell Carcinoma, Deglutition Disorders

NCT05611463 2022-11-10

CHANCE

25 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02436733 2022-11-07

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Other solid neoplasmThoracic

64 enrolled

Mesothelioma, Malignant

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

HER2-negative Breast Cancer

NCT05410197 2022-10-12

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

43 enrolled

Advanced Biliary Tract Cancer

NCT05574998 2022-10-12

FTANLCNDG

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05551767 2022-09-23

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

120 enrolled

Head and Neck Neoplasms

NCT05522894 2022-08-31

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

20 enrolled

Genitourinary

Urothelial Carcinoma Bladder

NCT05476380 2022-07-27

Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

39 enrolled

Esophageal Neoplasms

NCT04297267 2022-07-22

nonpCR GP

100 enrolled

Triple Negative Breast Neoplasms

NCT05469061 2022-07-21

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

17 enrolled

Esophageal Squamous Cell Carcinoma

NCT03946969 2022-07-19

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT02341911 2022-04-20

TNBC

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04192903 2022-04-20

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

55 enrolled

Triple Negative Breast Neoplasms

NCT02499367 2022-03-22

TONIC

84 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04390958 2022-03-15

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

70 enrolled

Esophageal Squamous Cell Carcinoma

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

60 enrolled